*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

| | |
|---|---|
| **Name of entity** | **LTR Pharma Limited** |
| **ABN** | **42 103 087 449** |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director** | Lee Rodne |
| **Date of last notice** | 20 November 2025 |

**Part 1 - Change of director's relevant interests in securities**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or indirect interest** | Direct |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | Not applicable |
| **Date of change** | 4 November 2026 |
| **No. of securities held prior to change** | Direct<br>1,129,641 Fully Paid Ordinary Shares<br><br>1,000,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028<br><br>100,000 Unlisted Options exercisable at $2.52 per option expiring 2 December 2028<br><br>2,000,000 Unlisted Options exercisable at $0.5075 per option expiring 24 October 2029<br><br>Indirect<br>46,373,750 Fully Paid Ordinary Shares held by LTR Medical Pty Ltd<br><br>982,143 Fully Paid Ordinary Shares held by LTR Consulting Pty Ltd<br><br>4,188,000 Fully Paid Ordinary Shares held by Trexapharm Inc |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **Class** | Unlisted Options |
| **Number acquired** | 2,000,000 |
| **Number disposed** | Not applicable |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and estimated valuation | Nil consideration |
| **No. of securities held after change** | Direct<br>1,129,641 Fully Paid Ordinary Shares<br><br>1,000,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028<br><br>100,000 Unlisted Options exercisable at $2.52 per option expiring 2 December 2028<br><br>2,000,000 Unlisted Options exercisable at $0.5075 per option expiring 24 October 2029<br><br>2,000,000 Unlisted Options exercisable at $0.674 per option expiring 23 October 2030<br><br>Indirect<br>46,373,750 Fully Paid Ordinary Shares held by LTR Medical Pty Ltd<br><br>982,143 Fully Paid Ordinary Shares held by LTR Consulting Pty Ltd<br><br>4,188,000 Fully Paid Ordinary Shares held by Trexapharm Inc |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of 2,000,000 Unlisted Options under the Employee Incentive Plan as approved by shareholders at the Company's 2026 Annual General Meeting (Resolution 5) |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | Not applicable |
| **Nature of interest** | Not applicable |
| **Name of registered holder (if issued securities)** | Not applicable |

| | |
|---|---|
| **Date of change** | Not applicable |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | Not applicable |
| **Interest acquired** | Not applicable |
| **Interest disposed** | Not applicable |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | Not applicable |
| **Interest after change** | Not applicable |

## Part 3 – +Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | No |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | Not applicable |
| **If prior written clearance was provided, on what date was this provided?** | Not applicable |

+ See chapter 19 for defined terms.